Sunday, 16 August 2026European Markets
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Move to Shore Up Trust as Leadership Shifts and AI-Adjacent Markets Wobble
Major AI and media platforms are converging on trust and accountability measures — Anthropic's Claude adding watermarks, Spotify labeling AI artists — just as OpenAI loses special-projects lead Brad Lightcap and Meta's Zuckerberg publishes a defensive manifesto on AI's societal role. In parallel, AI-adjacent financial dynamics are surfacing real stress: Wall Street firms are paying for privileged early access to Trump's Truth Social posts for trading edge, while Trump Media itself reports a $238M loss driven by falling crypto holdings, highlighting how information asymmetry and speculative digital assets are becoming entangled with AI-era platforms.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,809
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,809 facts checked against source5,205 source documents archived
Work with this data → vianewsagency.com

NICOX Stock Impressive Jump 32% So Far On Friday, Outperforms Market

Loading stream...

(vianews) - shares of nicox (cac 40: cox.pa) jumped by a staggering 32.53% to €0.77 at 11:05 est on friday, following the last session's downward trend. cac 40 is jumping 0.26% to €7,500.04, after four sequential sessions in a row of gains. this seems, at the moment, a somewhat up trend exchanging session today.

nicox's last close was €0.58, 72.06% below its 52-week high of €2.09.

about nicox

nicox s.a. operates as an ophthalmology company in france and internationally. the company develops solutions to maintain vision and improve ocular health. its lead product candidate is ncx 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. the company is also developing ncx 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and ncx 1728.it offers vyzulta, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and zerviate, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. the company was founded in 1996 and is headquartered in valbonne, france.

earnings per share

as for profitability, nicox has a trailing twelve months eps of €-1.26.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -43.38%.

sales growth

nicox's sales growth for the current quarter is 158%.

volume

today's last reported volume for nicox is 834147 which is 719.88% above its average volume of 101739.

volatility

nicox's last week, last month's, and last quarter's current intraday variation average was a negative 0.51%, a negative 2.06%, and a positive 2.51%.

nicox's highest amplitude of average volatility was 1.43% (last week), 3.12% (last month), and 2.51% (last quarter).

yearly top and bottom value

nicox's stock is valued at €0.77 at 11:05 est, way under its 52-week high of €2.09 and way higher than its 52-week low of €0.58.

more news about nicox (cox.pa).